Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan, Inc.    AGN

No quotes available
-- USD   0.00%
07:05p MAYNE PHARMA : to Acquire US Generics Product Portfolio from Teva an..
06/28 Teva, Allergan sell product lines to Australian co
06/28 MAYNE PHARMA : expands into US for $889m
SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

Allergan, Inc. : Allergan : Studies Show Botox Treats Overactive Bladder

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/28/2012 | 03:54pm CEST

Allergan Inc. (AGN) filed applications with U.S. and European regulators for approval to sell Botox as a treatment for overactive bladder as two Phase III clinical trials showed the injectible neurotoxin significantly reduced urinary incontinence when compared with a placebo.

Botox is approved for both cosmetic use, such as fighting wrinkles, and for various medical issues, including urinary incontinence in patients with neurologic conditions such as spinal-cord injury and multiple sclerosis.

Allergan on Wednesday said Botox met the primary endpoints of significantly reducing urinary incontinence, or bladder leakage, episodes in patients who have an inadequate response to or are intolerant of an anticholinergic medication.

Based on the results, Allergan has submitted a supplemental biologics license application with the U.S. Food and Drug Administration and an application with European Regulatory authorities to approve the use of Botox by adult patients not managed by an anticholinergic treatment.

The drug maker has been expanding its pipeline of late, such as buying Vicept Therapeutics Inc., the developer of a cream to treat rosacea, and striking a deal with Map Pharmaceuticals Inc. (MAPP) to jointly promote Map's experimental migraine treatment Levadex.

Allergan reported last month its fourth-quarter earnings rose 6.3% as higher specialty pharmaceuticals sales contributed to a 7.1% revenue jump.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on ALLERGAN, INC.
07:05p MAYNE PHARMA : to Acquire US Generics Product Portfolio from Teva and Allergan
06/28 Teva, Allergan sell product lines to Australian co
06/28 MAYNE PHARMA : expands into US for $889m
06/28 ASTRAZENECA : Announces new antibiotic zavicefta approved in the european union ..
06/23 ALLERGAN : Announces FDA Approval of Supplemental New Drug Application (sNDA) fo..
06/21 ULTRAGENYX PHARMACEUTICAL : Appoints Karah Parschauer as Executive Vice Presiden..
06/21 ALLERGAN : ZYDUS HEALTHCARE BUYS TWO ANDAs FROM TEVA
06/20 ALLERGAN : 1 Stock to Invest in Big Pharma
06/20 ALLERGAN : Ultragenyx Appoints Karah Parschauer as Executive Vice President, Gen..
06/18 Teva sells products to Sagent Pharma to fulfil Allergan Generics deal conditi..
Advertisement
Income Statement Evolution
More Financials